Annexon
Latest round
- Series D
Last raised
- Jun 2020
Total raised
- $225M
Investors
- 16
About Annexon
, Annexon, Inc. is a provider of complement-targeted therapies to patients suffering from autoimmune, neurodegenerative, and ophthalmic diseases, focusing on blocking the classical complement pathway. In June 2024, Annexon, Inc.58 apiece on the Nasdaq Global Select Market.750 million shares. The firm trades on NASDAQ under the ticker symbol ANNX. The company provides a wide range of therapeutic solutions targeting the classical complement pathway. The firm's key offerings include the C1q-blocking antibody ANX005 for Guillain-Barré syndrome and ANX007 for other complement-mediated diseases.
Who invested in Annexon
16 investors across 4 rounds
See all investors in Annexon
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Annexon
Who invested in Annexon?
Annexon has 16 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Annexon raised?
Annexon has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Annexon last raise money?
Annexon's most recent round on record is a Series D, in Jun 2020.
What does Annexon do?
Annexon is a biotechnology company.
Where is Annexon headquartered?
Annexon is headquartered in Brisbane, US.
Which VCs invest in companies like Annexon?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Annexon's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Annexon? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.